利用树突状细胞制备癌症疫苗。
Harnessing dendritic cells to generate cancer vaccines.
作者信息
Palucka Karolina, Ueno Hideki, Fay Joseph, Banchereau Jacques
机构信息
Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA.
出版信息
Ann N Y Acad Sci. 2009 Sep;1174:88-98. doi: 10.1111/j.1749-6632.2009.05000.x.
Abstract
Passive immunotherapy of cancer (i.e., transfer of T cells or antibodies) can lead to some objective clinical responses, thus demonstrating that the immune system can reject tumors. However, passive immunotherapy is not expected to yield memory T cells that might control tumor outgrowth. Active immunotherapy with dendritic cell (DC) vaccines has the potential to induce tumor-specific effector and memory T cells. Clinical trials testing first-generation DC vaccines pulsed with tumor antigens provided a proof-of-principle that therapeutic immunity can be elicited. Newer generation DC vaccines are built on the increased knowledge of the DC system, including the existence of distinct DC subsets and their plasticity all leading to the generation of distinct types of immunity. Rather than the quantity of IFN-gamma-secreting CD8(+) T cells, we should aim at generating high-quality, high-avidity, polyfunctional effector CD8(+) T cells able to reject tumors and long-lived memory CD8(+) T cells able to prevent relapse.
摘要
癌症的被动免疫疗法（即T细胞或抗体的转移）可导致一些客观的临床反应，从而证明免疫系统能够排斥肿瘤。然而，被动免疫疗法预计不会产生可能控制肿瘤生长的记忆T细胞。使用树突状细胞（DC）疫苗的主动免疫疗法有潜力诱导肿瘤特异性效应T细胞和记忆T细胞。对用肿瘤抗原脉冲处理的第一代DC疫苗进行的临床试验提供了一个原理证明，即可以引发治疗性免疫。新一代DC疫苗建立在对DC系统的更多了解之上，包括不同DC亚群的存在及其可塑性，所有这些都导致产生不同类型的免疫。我们的目标不应是分泌γ干扰素的CD8(+) T细胞的数量，而应是产生能够排斥肿瘤的高质量、高亲和力、多功能效应CD8(+) T细胞以及能够预防复发的长寿记忆CD8(+) T细胞。
相似文献
1
Harnessing dendritic cells to generate cancer vaccines.利用树突状细胞制备癌症疫苗。
Ann N Y Acad Sci. 2009 Sep;1174:88-98. doi: 10.1111/j.1749-6632.2009.05000.x.
2
Building on dendritic cell subsets to improve cancer vaccines.基于树突状细胞亚群改善癌症疫苗。
Curr Opin Immunol. 2010 Apr;22(2):258-63. doi: 10.1016/j.coi.2010.02.010. Epub 2010 Mar 11.
3
Taming cancer by inducing immunity via dendritic cells.通过树突状细胞诱导免疫来控制癌症。
Immunol Rev. 2007 Dec;220:129-50. doi: 10.1111/j.1600-065X.2007.00575.x.
4
Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.单次注射CD34+祖细胞来源的树突状细胞疫苗可诱导IV期黑色素瘤患者的T细胞免疫。
J Immunother. 2003 Sep-Oct;26(5):432-9. doi: 10.1097/00002371-200309000-00006.
5
Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.在经皮给予慢病毒载体疫苗接种后，常规树突状细胞是对模型抗原的辅助依赖性 CD8 T 细胞应答的激活所必需的。
J Immunol. 2011 Apr 15;186(8):4565-72. doi: 10.4049/jimmunol.1002529. Epub 2011 Mar 9.
6
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.接受CD34+祖细胞来源的树突状细胞疫苗接种的转移性黑色素瘤患者中黑色素瘤特异性细胞溶解CD8+ T细胞前体的扩增
J Exp Med. 2004 Jun 7;199(11):1503-11. doi: 10.1084/jem.20032118. Epub 2004 Jun 1.
7
Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma.与 IFN-γ联合使用临床级 TLR 激动剂诱导树突状细胞成熟可增强肿瘤特异性 CD8+T 细胞的诱导。
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):35-50. doi: 10.1177/039463201002300104.
8
Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.用人黑色素瘤肿瘤细胞裂解物或gp100肽（280-288）刺激的人树突状细胞，可诱导出具有相似表型和裂解活性的T细胞培养物对。
Cell Immunol. 1998 May 25;186(1):63-74. doi: 10.1006/cimm.1998.1298.
9
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.负载灭活同种异体黑色素瘤细胞的树突状细胞可诱导客观临床反应和MART-1特异性CD8 + T细胞免疫。
J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b.
10
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.摄取抗原特异性树突状细胞释放的外泌体的非特异性CD4(+) T细胞刺激抗原特异性CD8(+) CTL反应和长期T细胞记忆。
J Leukoc Biol. 2007 Oct;82(4):829-38. doi: 10.1189/jlb.0407249. Epub 2007 Jul 11.
引用本文的文献
1
Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.基于季戊四醇的脂质 A 增强了基于聚酸酐颗粒的癌症疫苗的抗肿瘤疗效。
Nanomedicine. 2019 Oct;21:102055. doi: 10.1016/j.nano.2019.102055. Epub 2019 Jul 15.
2
Distinct features of dendritic cell-based immunotherapy as cancer vaccines.基于树突状细胞的免疫疗法作为癌症疫苗的独特特征。
Clin Exp Vaccine Res. 2018 Jan;7(1):16-23. doi: 10.7774/cevr.2018.7.1.16. Epub 2018 Jan 29.
3
Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets.由特殊人类树突状细胞亚群传授的对病原体的免疫
Front Immunol. 2015 Oct 13;6:527. doi: 10.3389/fimmu.2015.00527. eCollection 2015.
4
Dendritic cell targeted vaccines: Recent progresses and challenges.树突状细胞靶向疫苗：最新进展与挑战
Hum Vaccin Immunother. 2016 Mar 3;12(3):612-22. doi: 10.1080/21645515.2015.1105415.
5
Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.布鲁氏菌属鲁马嗪合酶诱导小鼠对B16黑色素瘤产生TLR4介导的保护性反应。
PLoS One. 2015 May 14;10(5):e0126827. doi: 10.1371/journal.pone.0126827. eCollection 2015.
6
Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses.巨噬细胞和中性粒细胞衍生的肿瘤坏死因子-α指导皮肤朗格汉斯细胞启动抗病毒免疫反应。
J Immunol. 2014 Sep 1;193(5):2416-26. doi: 10.4049/jimmunol.1303339. Epub 2014 Jul 23.
7
In vivo delivery of nucleic acid-formulated microparticles as a potential tolerogenic vaccine for type 1 diabetes.作为1型糖尿病潜在的耐受性疫苗的核酸配制微粒的体内递送
Rev Diabet Stud. 2012 Winter;9(4):348-56. doi: 10.1900/RDS.2012.9.348. Epub 2012 Dec 28.
8
MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.MyD88 抑制增强树突状细胞的能力，通过 Th2 细胞促进胰腺癌发生。
J Exp Med. 2012 Aug 27;209(9):1671-87. doi: 10.1084/jem.20111706. Epub 2012 Aug 20.
9
Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity.天然剪接的 MHC Ⅰ类细胞胞质尾区变体增强树突状细胞诱导的 CD8+ T 细胞应答并增强抗肿瘤免疫。
PLoS One. 2011;6(8):e22939. doi: 10.1371/journal.pone.0022939. Epub 2011 Aug 10.
10
Comparative study of clinical grade human tolerogenic dendritic cells.临床级人诱导性树突状细胞的比较研究。
J Transl Med. 2011 Jun 9;9:89. doi: 10.1186/1479-5876-9-89.
本文引用的文献
1
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.生物标志物发现的新观念；美日肿瘤免疫分子标志物研讨会
J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.
2
Use of tumour-responsive T cells as cancer treatment.使用肿瘤反应性T细胞进行癌症治疗。
Lancet. 2009 Feb 21;373(9664):673-83. doi: 10.1016/S0140-6736(09)60404-9.
3
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.黄热病疫苗可诱导整合的多谱系和多功能免疫反应。
J Exp Med. 2008 Dec 22;205(13):3119-31. doi: 10.1084/jem.20082292. Epub 2008 Dec 1.
4
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.系统生物学方法预测黄热病疫苗在人体中的免疫原性。
Nat Immunol. 2009 Jan;10(1):116-125. doi: 10.1038/ni.1688. Epub 2008 Nov 23.
5
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.人类表皮朗格汉斯细胞和CD14+真皮树突状细胞的功能特化
Immunity. 2008 Sep 19;29(3):497-510. doi: 10.1016/j.immuni.2008.07.013.
6
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.一种用于血液基因组学研究的模块化分析框架：在系统性红斑狼疮中的应用。
Immunity. 2008 Jul 18;29(1):150-64. doi: 10.1016/j.immuni.2008.05.012.
7
Cancer immunology.癌症免疫学
N Engl J Med. 2008 Jun 19;358(25):2704-15. doi: 10.1056/NEJMra072739.
8
Reengineering dendritic cell-based anti-cancer vaccines.重塑基于树突状细胞的抗癌疫苗。
Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x.
9
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.转移性黑色素瘤患者体内循环肿瘤抗原特异性调节性T细胞
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20884-9. doi: 10.1073/pnas.0710557105. Epub 2007 Dec 18.
10
Taming cancer by inducing immunity via dendritic cells.通过树突状细胞诱导免疫来控制癌症。
Immunol Rev. 2007 Dec;220:129-50. doi: 10.1111/j.1600-065X.2007.00575.x.
Zotero 插件